Volume 9 Supplement 12
Finding microRNA regulatory modules in human genome using rule induction
© Tran et al; licensee BioMed Central Ltd. 2008
Published: 12 December 2008
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules (20–24 nt), which are believed to participate in repression of gene expression. They play important roles in several biological processes (e.g. cell death and cell growth). Both experimental and computational approaches have been used to determine the function of miRNAs in cellular processes. Most efforts have concentrated on identification of miRNAs and their target genes. However, understanding the regulatory mechanism of miRNAs in the gene regulatory network is also essential to the discovery of functions of miRNAs in complex cellular systems. To understand the regulatory mechanism of miRNAs in complex cellular systems, we need to identify the functional modules involved in complex interactions between miRNAs and their target genes.
We propose a rule-based learning method to identify groups of miRNAs and target genes that are believed to participate cooperatively in the post-transcriptional gene regulation, so-called miRNA regulatory modules (MRMs). Applying our method to human genes and miRNAs, we found 79 MRMs. The MRMs are produced from multiple information sources, including miRNA-target binding information, gene expression and miRNA expression profiles. Analysis of two first MRMs shows that these MRMs consist of highly-related miRNAs and their target genes with respect to biological processes.
The MRMs found by our method have high correlation in expression patterns of miRNAs as well as mRNAs. The mRNAs included in the same module shared similar biological functions, indicating the ability of our method to detect functionality-related genes. Moreover, review of the literature reveals that miRNAs in a module are involved in several types of human cancer.
MicroRNAs (miRNAs) are a class of small non-coding RNA molecules (20-24 nt), which are believed to participate in down-regulation of gene expressions. They inhibit their target genes (mRNA) in the post-transcriptional process by complementary base pairing [1–3]. Currently, 475 human miRNAs have been annotated in the miRNA registry, with over 1,000 miRNAs predicted to exist in humans. These miRNAs are predicted to target one-third of all genes in the genome, where each miRNA is expected to target around 200 transcripts [4, 5]. Recent studies have shown that miRNA can play fundamentally important roles in animal and plant development [1–3] as well as in genetic diseases including various types of cancer [6–9]. Therefore, discovering the functions of miRNA in living cells is an important task in biology.
Up to now, researchers have made many attempts to understand the functions of miRNAs in cellular processes more clearly, using both experimental and computational methods. Most efforts have concentrated on finding miRNAs and their targets [10–13]. However, understanding the regulatory mechanism of miRNAs in the gene regulatory network is also essential to the discovery of functions of miRNAs in complex cellular systems. In animal cells, miRNA regulatory mechanism is represented by the relationships between miRNAs and their targets at the post-transcriptional level of the gene regulation network. Furthermore, the relationship between miRNAs and their target genes is generally complicated. One target gene could be regulated by several miRNAs and conversely, one miRNA may have several target genes [1, 2, 7].
In order to understand the regulatory mechanism of miRNAs in complex cellular systems and to discover important patterns hidden in the complex interactions, we need to identify the functional modules involved in complex interactions between miRNAs and their target genes [14, 15]. Previously, Yoon and De Micheli introduced the concept of miRNA regulatory modules (MRMs) , which are defined as groups of miRNAs and their target genes that are believed to have similar functions or to be involved in similar biological processes. They represented the multiple relations between miRNAs and target genes by a weighted bipartite graph, and then used a five-step method to find MRMs . The main drawback of their method is that it deals only with miRNA-mRNA duplexes at the sequence level. Using only this kind of information may not be sufficient for determining MRMs. Other information such as miRNA and mRNA expression profiles could be also useful to detect the natural MRMs in a specific biological process [16, 17]. Another approach, proposed by Joung et al. , tries to combine multiple information sources to extract the MRMs. This method, however, relies on a genetic algorithm that undergoes several random processes. Therefore, the quality of their result depends on many sensitive parameters, thus making it unreliable.
As we know that miRNAs regulate expression by binding to cis-regulatory regions of 3'-UTR regions of genes, it is therefore reasonable to assume that genes regulated by the same miRNAs should contain similar expression profiles. This assumption initializes our analysis of human miRNA-target binding data and gene expression data to reveal the combinatorial nature of gene regulation at the post-transcription level. In this paper, we present a new computational method using rule learning to perform a comprehensive analysis of the combinatorial nature of gene regulation by detecting rules that identify a set of miRNAs associated with genes. The method extracts IF-THEN rules of miRNA combinations shared by target genes with a common expression profile. Similar to the approach of Joung et al. , our method also uses multiple information sources, including miRNA-target binding information, gene expression and miRNA expression profiles. However, the rule learning method allowed us to find the combinatorial nature of miRNA regulatory network without using any random process. As a result, the MRMs, found by our method, consist of highly-related miRNAs and their target genes with respect to biological processes. Moreover, evaluating MRMs by using the literature suggests that miRNAs in a module are involved in several types of cancer, and genes in the module indeed share common roles in biological processes.
Results and discussion
Finding potential miRNA regulatory modules
Summary of miRNA regulatory rules induced by our method (confidence ≥ 0.75 and coverage ≥ 3)
We evaluated rules using the concept of confidence and coverage. Confidence indicates the exactness of the rules and defined as confidence = p/P; where p is the number of examples of positive class (i.e. similarity class) covered by the rule, and P is the number of all examples in the dataset covered by the rule. Coverage indicates the generality of the rules (i.e. the number of examples of positive class covered by the rule) and defined as coverage = p. Rule induction may produce a large number of very specific rules (i.e. rules with low coverage), indicating that no general relationship could be found between miRNA-binding information and expression data for these target genes. Other rules will cover many genes with a large diversity in their expression profiles (i.e. rules with low accuracy), violating the assumption that genes regulated by the same miRNAs should be coexpressed. Only when we find miRNA combinations common to several target genes with similar expression may we expect a high probability for actual coregulation.
Examples of potential miRNA regulatory rules (PCC = 0.2)
[NOVA1, ST8SIA4, ZFP36L1]
[DAG1, NEDD9, YES1, BMPR2, PTPRF]
[PCAF, NOVA1, EIF4A2]
[NOVA1, ZNF238, WEE1, ELL2, MAP3K14, PKIA, APC, ADD3]
[NOVA1, CDH5, ADD3]
[hsa-miR-101, hsa-miR-19a, hsa-miR-221]
[ATXN1, CTCF, RAB1A]
[ARID3A, TAF5, HAS2, NOVA1, AKAP6, DYRK1A]
[BCL2L2, PLAG1, SP1, CBX1]
[CIC, EDG1, SSFA2, PCAF, SALL1]
[KPNA3, RUNX1T1, EPHA7]
[DYRK1A, MAPRE1, BCL9]
[ZNF238, EPHA7, CDH2]
[PRDM2, DOCK3, DPF2]
[SOCS1, NOVA1, NR2F2, PAPOLA, ELL2]
[DYRK1A, MMD, YES1, MAPK9, SMAD1]
[PLEKHC1, PTEN, INA]
[YES1, SLC35A1, FGF9]
[MMD, CAPZA1, SMAD1]
[MMD, PCAF, ANK3, ADAMTS3]
[DYRK1A, YES1, BAMBI, MKNK1]
[EGR3, RARB, MAP3K8]
[BCL2L2, MAP7, SRPK1, SMAD7]
[CACNB2, CLCN3, UBE4A, PPM1G]
[hsa-miR-101, hsa-miR-218, hsa-miR-22]
[FBN2, TLK2, BCL9]
[ATP2B1, ATXN1, PLAG1, ESR1]
[RANBP2, GNAI3, POU4F1, CDC2L5]
[NR3C2, ATP1B1, CUL4A]
[MAPRE1, MAP3K12, PAPOLA]
[EPHA4, TRAM1, RCN2]
Validation using gene ontology
With the current knowledge of combinatorial coregulation, it is hard for us to directly validate potential MRMs. Fortunately, using Gene Ontology (GO)  we can validate the target genes in each MRM with respect to biological processes, cellular components and molecular functions. This validation can be achieved by searching for statistically significant GO terms.
Biological processes of potential miRNA regulatory modules annotated in GO 
Multicellular organismal process
NOVA1, ST8SIA4, ZFP36L1
Macromolecule biosynthetic process
Cell surface receptor linked signal transduction
NEDD9, BMPR2, PTPRF
Protein metabolic process
DAG1, YES1, BMPR2, PTPRF
Protein modification process
YES1, BMPR2, PTPRF
PCAF, NOVA1, EIF4A2
N-terminal peptidyl-lysine acetylation
Negative regulation of transferase activity
Negative regulation of protein kinase activity
Supporting evidence of miRNA associated with cancers
Recent studies have shown that several miRNAs are directly involved in human cancers (including lung, breast, brain, liver, and colon cancer) [20–22]. This is because more than 50% of miRNA genes are located in cancer-associated genomic regions or fragile sites . This evidence suggests that miRNAs may play a more important role in human cancers than was previously thought. Therefore, we validated the found modules with supporting evidence from the literature. Interestingly, several modules have been confirmed to be related to lung and other human cancers. For example, module 1 contains two miRNAs (hsa-miR-143 and hsa-miR-181b) and three target genes (NOVA1, ST8SIA4, and ZFP36L1). Both hsa-miR-143 and hsa-miR-181b are related to colorectal cancer [24, 25]. Specifically, Micheal et al.  reported that hsa-miR-143 had decreased expression in both tumorigenic and precancerous tissues compared to normal samples. Several cancer cell lines (including colorectal adenocarcinoma and breast carcinoma) were also found to have decreased expression levels of hsa-miR-143 . The expression level of hsa-miR-181b was investigated in the study of Xi et al. . Their analysis revealed that hsa-miR-181b had high expression level in tumors displaying p 53 deletion, and hsa-miR-181b expression level was strongly associated with the mutation status of the p 53 in tumor.
Of these target genes in this module, NOVA1 encodes a neuron-specific RNA-binding protein, a member of the Nova family of paraneoplastic disease antigenes that is recognized and inhibited by paraneoplastic antibodies. These antibodies are found in the sera of patients with breast cancer and small cell lung cancer . ST8SIA4 encodes a type II membrane protein, which is a member of glycosyltransferase family 29 and may be present in the Golgi apparatus. Although this gene is considered as a member of genes coding for membrane protein, it can show differences in expression levels between malignant and non-malignant tumor . The last one, ZFP36L1, is a member of the TIS11 family of early response genes. This gene is well conserved across species and has a promoter that contains motifs seen in other early-response genes. It may have a role as an oncogene.
Module 2 consists of two miRNAs (hsa-miR-145 and hsa-miR-125b) and five target genes (DAG1, NEDD9, YES1, BMPR2, and PTPRF). Iorio et al.  analyzed the expression of 76 breast cancer and 10 normal breast samples to identify miRNAs whose expressions are significantly deregulated in cancer versus normal breast tissues. They reported that hsa-miR-125b and hsa-miR-145 were indeed involved in human breast cancer . While hsa-miR-125b was down-regulated, hsa-miR-145 was up-regulated in human breast cancer. Their analysis suggested that these miRNAs may potentially act as tumor suppressors. Furthermore, expression of hsa-miR-145 was found at a low level in lung cancer tissues compared to normal samples . Based on the target prediction and expression level of hsa-miR-145 in human cancers, Akao et al.  also suggested that this miRNA may suppress genes involved in signal transduction and oncogenesis.
Of five target genes in this module, three of them (NEDD9, BMPR2, and PTPRF) are involved in cell surface receptor linked signal transduction, and others are involved in protein metabolic process in terms of GO categories (Table 3). Interestingly, all genes also have roles in development of several type of cancers. For example, PTPRF encoded proteins which are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. The PTPRF gene also plays important roles in colorectal cancers  and kidney carcinomas . Therefore, it is reasonable for us to conclude that our predicted MRM modules are really related to human cancers.
Selected miRNAs associated with human cancers
Type of cancer
Colorectal, colon and breast cancer
Breast cancer, Hodgkin lymphoma
Breast colon, and lung cancer
MYC, Lung cancer and B-cell lymphomas
B-cell chronic lymphocytic leukemia
Papillary thyroid carcinoma, lung cancer
Colorectal and colon cancer
Papillary thyroid carcinoma, B-cell lymphoma, colorectal cancer
Papillary thyroid carcinoma
Papillary thyroid carcinoma, breast cancer
Acute myeloid leukaemia
Breast cancer metastasis
Although numerous miRNAs have recently been discovered in some species, their precise functional roles in cellular processes are still largely unknown. Specifically, the relationships between miRNAs and their target genes are less understood. In this paper we introduced a new computational method for finding MRMs from their predicted target genes and expression datasets (mRNA expression profiles and miRNA expression profiles). By combining these information sources, we can discover relevant MRMs in human genome.
In MRMs, found by our method, expression patterns of miRNAs as well as mRNAs were highly correlated. The mRNAs included in the same module also shared similar biological functions, indicating the ability of our method to detect functionality-related genes. Moreover, we also analyzed the relationships between several cancer diseases and our MRMs by using the literature. This analysis revealed that miRNAs in a module are involved in several types of cancer and genes in the module indeed share common roles in biological processes.
Despite these benefits of our method, several issues require further investigation. First, our rule induction method still produces a lot of rules. Many of them may be insignificant. New rule evaluation heuristic approaches could be used to reduce the search rule space. Second, the quality of MRMs obtained by our method depends on the choice of the similarity measure. In this paper, we have used the Pearson's correlation coefficient. However, other measures with the similar properties could be used for further study.
In our experiments, we extracted the expression profiles of miRNAs and mRNAs from the experimental data previously published by Lu et al. . This dataset consists of 217 miRNAs and about 16,063 mRNAs on 89 multiple human cancer samples. The current miRNA target prediction methods are mainly based on the principle of miRNA-target interactions, and the accuracy of these methods has been confirmed by experimental validation of randomly selected miRNA targets  and by large-scale gene expression profiling studies . Though there are several available miRNA target prediction methods such as PicTar, miRanda, and TargetScan, a recent study indicated that PicTar had the highest success rate in target gene prediction . Moreover, up to 90% of the randomly selected miRNA targets from the predictions by PicTar have been validated as true targets . We thus utilized PicTar algorithm  for obtaining predicted target genes of each miRNAs.
The Pearson's correlation coefficient
where x i and y i are the i th sample values of genes x and y, respectively; and are mean values obtained from m samples of genes x and y, respectively. The PCC of a pair of genes commonly returns a real value in [+1, -1]. PCC(x, y) > 0 represents that x and y are positively correlated with the degree of correlation. On the other hand, PCC(x, y) < 0 represents that x and y are negatively correlated with a value |PCC(x, y)|. A positive value of the PCC indicates that two genes are co-expressed and a negative value of the PCC indicates that opposite expression pattern exists between them. We can see that with this measure, genes with low- and high-expression values may be placed in the same cluster if they have similar patterns of changes in expression values over the samples. The advantage of the PCC over the Euclidean measure is that the Euclidean methods find mainly spherical shape of clusters, even if the shape of clusters may not be present in the dataset. The PCC is used as a measure of similarity/dissimilarity of cluster genes with similar expression patterns.
Rule induction is a machine learning technique that has been successfully applied in subgroup discovery. The problem of subgroup discovery can be defined as follows: given a population of individuals and a property of those individuals we are interested in, find population subgroups that are interesting with respect to the property of interest . The induced rules usually have the form Cond → Class, where Class is a value of the property of interest, and Cond is a conjunction of attribute-value pairs selected from the features describing the training instances. In our case, Class has two values, similarity and dissimilarity. Attributes are miRNAs and attribute-value is 0 or 1.
In general, there are three strategies for inducing rules (describing individual interesting patterns) from data: separate-and-conquer, divide-and-conquer and exhaustive search . The separate-and-conquer strategy searches for a rule that covers part of its training instances, separates (or reassigns with lower weight) these examples, and recursively conquers the remaining examples by learning more rules until no examples remain. The divide-and-conquer strategy is used in decision tree algorithms; this strategy is restricted to learning non-overlapping rules only. The exhaustive search strategy explores almost all of the whole search space. The basic idea is to use an association rule algorithm to gather all rules that predict the class attribute and also pass a minimum quality criterion.
By implementation, the divide-and-conquer strategy (in decision tree-based algorithms) is restricted to learn non-overlapping rules only. The exhaustive strategy (in association rule-based algorithms) has the problem of producing many redundant rules. The separate-and-conquer algorithms can partially avoid these disadvantages [36, 38], which is one of the main reasons for its popularity.
CN2 is a rule induction system implementing the separate-and-conquer strategy . It learns a rule set by iteratively adding rules one at a time. Examples covered by the rule are removed from the search space before learning the next rule to add to the rule set. This is repeated until all examples are covered by at least one rule in the rule set or some stopping criteria is satisfied. Finally, CN2 can induce a set of independent rules, where each rule describes a specific subgroup of instances. This is not suitable for description tasks (discovering individual rules describing interesting patterns, as in this work). Since CN2 only induces the first few rules discovered are usually interesting. Subsequently induced rules are obtained from biased example subsets, i.e., subsets including only positive examples that are not covered by previously induced rules.
Though the CN2-SD rule induction system uses a weighted covering strategy to restrict the redundancy of learned rules and guarantee the scanning of the whole search space, uninteresting rules are still produced [36, 37]. Let us assume that our rule r has a form: IF [Cond] THEN [ClassDistribution]. Where Cond = [miR1 = val1∧miR2 = val2∧miR3 = val3∧...∧miR k = val k ] and Classdistribution = [p, n] is the class distribution of examples covered by r (miR i is a miRNA and val i = 0 or 1). We have used several heuristics to filter out unexpected rules. First, we remove trivial rules, r is called a trivial rule if the number of positive examples covered by r is less than 2. The reason is that the miRNAs in this rule only coregulate one gene, it is a trivial case. Second, if there is any miRNA in the Cond part of a rule which has a value equal to 0, this miRNA does not bind to the target genes of the corresponding rule. We also remove such rules. Third, we calculate the correlation coefficient between all miRNA pairs which appear in the same module. If the correlation coefficient of any miRNA pair is less than a given threshold, that rule will also be removed. This heuristic allows us to find MRMs which are not only highly correlated on target genes, but also highly correlated on miRNAs with respect to expression profiles.
The research described in this paper was partially supported by the Institute for Bioinformatics Research and Development of the Japan Science and Technology Agency, and by COE project JCP KS1 of the Japan Advanced Institute of Science and Technology. The first author has been supported by Japanese government scholarship (Monbukagakusho) to study in Japan. The authors would like to thank Prof. Nada Lavrac for providing us the newest version of CN2-SD software. We also would like to thank Dr. Tho Hoan Pham for sharing his experience on rule induction learning and his comments on the manuscript.
This article has been published as part of BMC Bioinformatics Volume 9 Supplement 12, 2008: Asia Pacific Bioinformatics Network (APBioNet) Seventh International Conference on Bioinformatics (InCoB2008). The full contents of the supplement are available online at http://www.biomedcentral.com/1471-2105/9?issue=S12.
- Ambros V: The functions of animal microRNAs. Nature 2004, 431: 350–355. 10.1038/nature02871View ArticlePubMedGoogle Scholar
- Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116: 281–297. 10.1016/S0092-8674(04)00045-5View ArticlePubMedGoogle Scholar
- Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T: Identification of novel genes coding for small expressed RNAs. Science 2001, 294: 853–858. 10.1126/science.1064921View ArticlePubMedGoogle Scholar
- Griffiths-Jones S, Grocock RJ, Dongen S, Bateman A, Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006, 34: D140-D144. 10.1093/nar/gkj112PubMed CentralView ArticlePubMedGoogle Scholar
- Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ: miRBase: Tools for microRNA genomics. Nucleic Acids Res 2008, 36: D154-D158. 10.1093/nar/gkm952PubMed CentralView ArticlePubMedGoogle Scholar
- Blenkiron C, Thorne L, Thorne N, Spiteri I, Chin S, Dunning M, Barbosa-Morais N, Teschendsoff A, Green A, Ellis I, Tavare S, Caldas C, Miska E: MicroRNA expression profiling of human breast cancer identifies new markers of tumour subtype. Genome Biol 2007,8(10):R214. 10.1186/gb-2007-8-10-r214PubMed CentralView ArticlePubMedGoogle Scholar
- He L, Hannon GJ: MicroRNAs: Small RNAs with a big role in gene regulation. Nature Review 2004, 5: 522–531. 10.1038/nrg1379View ArticleGoogle Scholar
- Hobert O: miRNAs play a tune. Cell 2007, 131: 22–24. 10.1016/j.cell.2007.09.031View ArticlePubMedGoogle Scholar
- Lu J, Getz G, Miska AE, Alvarez-Savedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert LB, Mak HR, Ferrando AA, Downing , Jacks T, Horvitz HR, Golub RT: MicroRNA expression profiles classify human cancers. Nature 2005, 435: 834–838. 10.1038/nature03702View ArticlePubMedGoogle Scholar
- Brown J, Sanseau P: A computational view of microRNAs and their targets. Drug discovery today: biosilico 2005,10(8):595–601.View ArticleGoogle Scholar
- Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z, Hatzigeorgiou A: A combined computational-experimental approach predicts human microRNA targets. Genes Dev 2004, 18: 1165–1178. 10.1101/gad.1184704PubMed CentralView ArticlePubMedGoogle Scholar
- Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein E, MacMenamin P, Piedade I, Gunsalus KC, Stoffel M, Rajewsky N: Combinatorial microRNA target predictions. Nature Genetics 2005, 37: 495–500. 10.1038/ng1536View ArticlePubMedGoogle Scholar
- Lai EC, Tomancak P, Williams RW, Rubin GM: Computational identification of Drosophila microRNA genes. Genome Biol 2003, 4: R42. 10.1186/gb-2003-4-7-r42PubMed CentralView ArticlePubMedGoogle Scholar
- Joung GJ, Hwang BK, Ban WJ, Kim JS, Zhang TB: Discovery of microRNA-mRNA modules via population-based probabilistic learning. Bioinformatics 2007,23(9):1141–1147. 10.1093/bioinformatics/btm045View ArticlePubMedGoogle Scholar
- Yoon S, Micheli GD: Prediction of regulatory modules comprising microRNAs and target genes. Bioinformatics 2005,21(2):ii93-ii99. 10.1093/bioinformatics/bti1116PubMedGoogle Scholar
- Huang JC, Morris QD, Frey BJ: Detecting MicroRNA Targets by Linking Sequence, MicroRNA and Gene Expression Data. Proc RECOMB 2006, 114–129.Google Scholar
- Zilberstein CB, Ziv-Ukelson M, Pinter RY, Yakhini Z: A High-Throughput Approach for Associating MicroRNAs with Their Activity Conditions. J Comput Biol 2006, 13: 245–266. 10.1089/cmb.2006.13.245View ArticlePubMedGoogle Scholar
- Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nature Genetic 2000, 25: 25–29. 10.1038/75556View ArticleGoogle Scholar
- Beissbarth T, Speed TP: GOstart: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics 2004, 20: 1464–1465. 10.1093/bioinformatics/bth088View ArticlePubMedGoogle Scholar
- Baohong Z, Xiaoping P, George PC, Todd AA: MicroRNAs as oncogenes and tumor suppressors. The New Eng J Med 2007, 353: 1767–1771.Google Scholar
- Dalmay T: MicroRNA and cancer. J Int Med 2008, 263: 1365–2796.View ArticleGoogle Scholar
- Wei W, Miao S, Gang-Ming Z, Jianjun C: MicroRNA and cancer: Current status and prospective. Int J Cancer 2006, 120: 953–960.View ArticleGoogle Scholar
- Calin GA, Sevignani C, Dan C, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, Croce CM: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004, 101: 2999–3004. 10.1073/pnas.0307323101PubMed CentralView ArticlePubMedGoogle Scholar
- Michael MZ, O'Connor SM, Pellekaan NG, Young GP, James RJ: Reduced accumulation of specific mi-croRNAs in colorectal neoplasia. Mol Cancer Res 2003,1(12):882–891.PubMedGoogle Scholar
- Xi Y, Shalgi R, Fodstad O, Pil Y, Ju J: Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res 2006, 12: 2014–2024. 10.1158/1078-0432.CCR-05-1853View ArticlePubMedGoogle Scholar
- Ueki K, Ramaswamy S, Billings SJ, Mohrenweiser HW, Louis DN: ANOVA, a putative astrocytic RNA-binding protein gene that maps to chromosome 19q13.3. Neurogenetics 1997, 1: 31–36. 10.1007/s100480050005View ArticlePubMedGoogle Scholar
- Zilberstein CB, Ziv-Ukelson M, Pinter RY, Yakhini Z: Altered Glycosylation in Cancer: Sialic Acids and Sialyltransferases. J of Cancer Molecules 2005,1(2):73–81.Google Scholar
- Iorio VM, et al.: MicroRNA Gene Expression Deregulation in Human Breast Cancer. Cancer Res 2005, 65: 7065–7070. 10.1158/0008-5472.CAN-05-1783View ArticlePubMedGoogle Scholar
- Yanaihara N, et al.: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006,9(3):189–198. 10.1016/j.ccr.2006.01.025View ArticlePubMedGoogle Scholar
- Akao Y, Nakagawa Y, Naoe T: MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 2006,16(4):845–850.PubMedGoogle Scholar
- Harder KW, Saw J, Miki N, Jirik F: Coexisting Amplifications of the Chromosome 1p32 Genes (PTPRF and MYCL1) Encoding Protein Tyrosine Phosphatase LAR and L-myc in a Small Cell Lung Cancer Line. Genomics 2002,27(3):552–553. 10.1006/geno.1995.1092View ArticleGoogle Scholar
- Cheburkin YV, et al.: Molecular Portrait of Human Kidney Carcinomas: The cDNA Microarray Profiling of Kinases and Phosphatases Involved in the Cell Signaling Control. Molecular biology 2002,36(3):376–384. 10.1023/A:1016059313254View ArticleGoogle Scholar
- Rajewsky N: MicroRNA target predictions in animals. Nat Genet 2006, 38: S8-S13. 10.1038/ng1798View ArticlePubMedGoogle Scholar
- Lim LP, Clau NC, Garret-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Jonson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433: 769–773. 10.1038/nature03315View ArticlePubMedGoogle Scholar
- Grun D, Wang Y, Langenberger D, Gunsalus K, Rajewsky N: MicroRNA target predictions across seven Drosophila species and comparison to mammalian targets. PLoS Comput Biol 2005, 1: e13. 10.1371/journal.pcbi.0010013PubMed CentralView ArticlePubMedGoogle Scholar
- Lavrac N, Kavsek B, Flach P, Todorovski L: Subgroup discovery with CN2-SD. J Machine Learning Res 2004, 5: 153–188.Google Scholar
- Pham TH, Clemente JC, Satou K, Ho TB: Computational discovery of transcriptional regulatory rules. Bioinformatics 2005, 21: ii101-ii107. 10.1093/bioinformatics/bti1117View ArticlePubMedGoogle Scholar
- Furnkranz J: Separate-and-Conquer Rule Learning. Artificial Intelligence Review 1999, 13: 03–54. 10.1023/A:1006524209794View ArticleGoogle Scholar
- Clark P, Nibblet T: The CN2 induction algorithm. Machine Learning 1989, 3: 261–283.Google Scholar
- Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A: High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer 2004, 39: 167–169. 10.1002/gcc.10316View ArticlePubMedGoogle Scholar
- Volinia S, et al.: A microRNA expression signature of human solid tumors defines cancer gene targets. PNAS 2006,103(7):2257–2261. 10.1073/pnas.0510565103PubMed CentralView ArticlePubMedGoogle Scholar
- He L, et al.: A microRNA polycistron as a potential human oncogene. Nature 2005, 435: 828–833. 10.1038/nature03552PubMed CentralView ArticlePubMedGoogle Scholar
- Calin GA, et al.: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002, 99: 15524–15529. 10.1073/pnas.242606799PubMed CentralView ArticlePubMedGoogle Scholar
- Yu SL, et al.: MicroRNA Signature Predicts Survival and Relapse in Lung Cancer. Cancer Cell 2008, 13: 48–57. 10.1016/j.ccr.2007.12.008View ArticlePubMedGoogle Scholar
- Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, Yamamoto M, Ju J: Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are Associated with Chemoresponse to S-1 in Colon Cancer. Cancer Genomics Proteomics 2006,3(5):317–324.PubMed CentralPubMedGoogle Scholar
- Xi Y, Formentini A, Chien M, Weir DB, Russo JJ, Ju J, Kornmann M, Ju J: Prognostic values of microRNAs in colorectal cancer. Biomark Insights 2006, 2: 113–121.PubMedGoogle Scholar
- Debernardi S, Skoulakis S, Molloy G, Chaplin T, Dixon-Mclver A, Young BD: MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia 2007, 21: 912–916.PubMedGoogle Scholar
- Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, Gerald WL, Massague J: Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451: 147–152. 10.1038/nature06487PubMed CentralView ArticlePubMedGoogle Scholar
- Johnson CD, et al.: The let-7 microRNA represses cell proliferation. Cancer Res 2007,67(16):7713–7722. 10.1158/0008-5472.CAN-07-1083View ArticlePubMedGoogle Scholar
- Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S: The Oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 2007,67(22):11001–11011. 10.1158/0008-5472.CAN-07-2416View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.